Clinical trials: Malignant Melanoma
Advanced Malignancies
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.
- Trial name
- NCT00948961
- Testing
- CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- Celldex Therapeutics
Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
MGC018 With or Without MGA012 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of vobramitamab duocarmazine (MGC018) in patients with advanced solid tumors.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult
- Trial name
- NCT03729596
- Testing
- vobramitamab duocarmazine
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 143 people
- Sponsor
- MacroGenics
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
This phase I/IIa trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens…
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma
- Trial name
- NCT02650986
- Testing
- Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Non-melanoma Skin Cancer
DERM NMSC Validation Study
This study aims to establish the effectiveness of an Artificial Intelligence (AI) algorithm (DERM) to determine the presence of Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) and frequently observed benign…
- Trial name
- NCT04116983
- Testing
- Deep Ensemble for the Recognition of Malignancy (DERM)
- Where
- 3 sites in United Kingdom
- Volunteers
- 572 people
- Sponsor
- Skin Analytics Limited
Cancer, Solid Tumor
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in…
- Conditions
- Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT04787042
- Testing
- ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 316 people
- Sponsor
- Simcha IL-18, Inc.
Mucosal Melanoma
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
This is a single arm phase II clinical trial of Ipilimumab and Nivolumab in patients with resected mucosal melanoma. Ipilimumab (1 mg/kg) and Nivolumab (3 mg/kg) will be administered Day 1 of a 21-day cycle in Cycles 1-4 and then…
- Trial name
- NCT03241186
- Testing
- Ipilimumab, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Robert R. McWilliams, MD
Melanoma (Skin), Carcinoma
App Teaches Doctors to Diagnose Skin Cancer
This study aimed to examine if self-paced learning with a novel digital patient-case-based educational platform can increase primary care physicians' diagnostic accuracy of malignant and benign skin lesions on both the level of…
- Trial name
- NCT05661370
- Testing
- Dermloop Learn
- Where
- Denmark
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Melanoma (Skin)
S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
RATIONALE: Thalidomide may stop the growth of melanoma by blocking blood flow to the tumor. It may also stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00104988
- Testing
- temozolomide, thalidomide
- Where
- 132 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
Malignant Melanoma
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in adults…
- Trial name
- NCT03820986
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 119 sites in United States, Australia and 16 more
- Volunteers
- 674 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
- Trial name
- RELATIVITY-098 (NCT05002569)
- Testing
- Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 1,093 people
- Sponsor
- Bristol-Myers Squibb
Malignant Melanoma
Quality of Life and Psychological Well-being in Patients With Malignant Melanoma
The purpose of this study is to analyse the physical and psychological side-effects in the course of treatment with IFN-alpha. The effectiveness of a specific intervention for the management of these side-effects is evaluated.
- Trial name
- NCT00963261
- Testing
- psycho-oncological intervention
- Where
- 2 sites in Germany
- Volunteers
- 600 people
- Sponsor
- University Hospital Freiburg
Melanoma
Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases
The research questions to be addressed by this study are as follows: 1. What is the prevalence of ipilimumab use among adults with a history of autoimmune disease that received treatment with ipilimumab for advanced melanoma? 2.
- Trial name
- NCT02739386
- Testing
- Ipilimumab
- Where
- United States
- Volunteers
- 370 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients
To improve the efficacy of immunotherapy for cancer, recent studies focused on specific targets to redirect the immune network toward eradicating a variety of tumors and ameliorating the self-destructive process.
- Trial name
- Nivo-TIL (NCT03374839)
- Testing
- TIL + IL-2 + Nivolumab
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Nantes University Hospital
Intraocular Melanoma, Melanoma (Skin)
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop tumor cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00058279
- Testing
- aldesleukin, ipilimumab
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Malignant Melanoma, Melanoma
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
RATIONALE: Drugs used in chemotherapy, such as FR901228, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00104884
- Testing
- Depsipeptide
- Volunteers
- 4 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Melanoma, Skin Cancer
Artificial Intelligence Augmented Training in Skin Cancer Diagnostics for General Practitioners
Background: The worldwide incidence of skin cancer has been rising for 50 years, in particular the incidence of malignant melanoma has increased approx. 2-7% annually and is the most common cancer amongst Danes aged 15-34.
- Trial name
- AISC-GP (NCT04576416)
- Testing
- AI augmented training and clinical feedback
- Where
- Denmark
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Gastrointestinal Cancer, Neuroendocrine Carcinoma
Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment
This single-blind, randomized controlled trial studies how well inhaled essential oils work for common quality of life concerns in patients who are undergoing cancer treatment such as chemotherapy, targeted therapy, and/or…
- Conditions
- Gastrointestinal Cancer, Neuroendocrine Carcinoma, Skin Cancer
- Trial name
- NCT03858855
- Testing
- Aromatherapy and Essential Oils, Subject Diary
- Where
- United States
- Volunteers
- 248 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Melanoma
Immunotherapy of Melanoma Patients
The purpose of this study is to test whether vaccination with antigenic peptides induces an immune response in the vaccine site sentinel lymph node of patients with microscopically detectable lymph node melanoma metastases.
- Trial name
- NCT00112216
- Testing
- Melan-A analog peptide, FluMa peptide, Mage-A10 peptide
- Where
- Switzerland
- Volunteers
- 9 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Recurrent Melanoma, Stage IIIA Melanoma
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
This phase II trial studies how well high-dose aldesleukin and ipilimumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT02203604
- Testing
- aldesleukin, ipilimumab, laboratory biomarker analysis
- Where
- 6 sites in United States
- Volunteers
- 9 people
- Sponsor
- CINJRegulatory
Melanoma, Head and Neck Cancer
In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
The purpose of this study is to evaluate the safety of sequential intratumoral (IT) plus intramuscular (IM) Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC, Hiltonol®) for…
- Conditions
- Melanoma, Head and Neck Cancer, Sarcoma, Non-Melanoma Skin Cancers
- Trial name
- Poly-ICLC (NCT02423863)
- Testing
- Hiltonol
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Oncovir, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.